Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GALE | Q14376 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11310644 | 0.75 | TP53 (0.42) | LMNATDP1TSHRHSD17B10 | |
| SCHEMBL4593313 | 0.75 | TDP1 (0.47) | NR1I2ADORA3SLC6A2SLC6A3LMNA | |
| SCHEMBL2641377 | 0.70 | NR1I2 (0.60) | NR1I2ADRA2AADORA3ADRA2BADRA2C | |
| SCHEMBL11315734 | 0.70 | ALDH1A1 (0.46) | SLC6A2SLC6A4SLC6A3TSHRAHR | |
| SCHEMBL28105594 | 0.69 | MPO (0.47) | NR1I2ADRA2AADORA3ADRA2BADRA2C | |
| SCHEMBL11715356 | 0.69 | NPC1 (0.41) | LMNAMAPK1TDP1TSHRL3MBTL1 | |
| SCHEMBL98679 | 0.69 | CA12 (0.45) | SLC6A2HTR2ASLC6A4SLC6A3KCNH2 | |
| SCHEMBL54888 | 0.68 | LMNA (0.47) | SLC6A2SLC6A4SLC6A3LMNATDP1 | |
| SCHEMBL2089456 | 0.67 | CYP3A4 (0.36) | MAPK1TDP1AHRFABP3 | |
| SCHEMBL95604 | 0.67 | HSP90AA1 (0.44) | SLC6A2SLC6A4SLC6A3LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5532171-A | PHENOTHIAZINE DYES FOR PHOTODYNAMIC THERAPY OF CANCER OR IMMUNOASSAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | claimed |
| US-5344928-A | Phenothiazine compounds for cancer treatment or immunoassay using chemiluminescence | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-09-06 | — | — | US | claimed |
| EP-0510668-A2 | Phenothiazine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-28 | — | — | EP | claimed |
| EP-0362634-A2 | Basic dihydropyridines, process for their preparation and their use as intermediates | BAYER AG (DE) | 1990-04-11 | — | — | EP | claimed |
| US-20070129288-A1 | Antibacterial amide macrocycles | BAYER HEALTHCARE AG (DE) | 2007-06-07 | — | — | US | disclosed |
| EP-1515983-B1 | ANTIBACTERIAL AMIDE MACROCYCLES | AICURIS GMBH & CO KG (DE) | 2007-02-21 | — | — | EP | disclosed |
| US-20060258571-A1 | Antibacterial ester macrocycles | AICURIS GMBH & CO. KG (DE) | 2006-11-16 | — | — | US | disclosed |
| EP-1526896-A1 | ANTIBACTERIAL ESTER MACROCYCLES | Bayer HealthCare AG (DE) | 2005-05-04 | — | — | EP | disclosed |
| EP-1515983-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004012816-A1 | ANTIBACTERIAL ESTER MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003106480-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2003-12-24 | — | — | WO | disclosed |
| US-5532171-A | PHENOTHIAZINE DYES FOR PHOTODYNAMIC THERAPY OF CANCER OR IMMUNOASSAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| EP-0412350-A2 | Renininhibitors, procedure for their preparation and use as medicaments | BAYER AG (DE) | 1991-02-13 | — | — | EP | disclosed |
| EP-0403828-A1 | Renin-inhibiting peptides, their preparation and their use in medicaments | BAYER AG (DE) | 1990-12-27 | — | — | EP | disclosed |
| EP-0393445-A2 | Use of peptide renin inhibitors as an agent against retrovirus | BAYER AG (DE) | 1990-10-24 | — | — | EP | disclosed |
| EP-0362634-A2 | Basic dihydropyridines, process for their preparation and their use as intermediates | BAYER AG (DE) | 1990-04-11 | — | — | EP | disclosed |
| EP-0356796-A2 | Aminomethyl peptides, production process and their use as medicaments | BAYER AG (DE) | 1990-03-07 | — | — | EP | disclosed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | disclosed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | disclosed |
| US-4259350-A | PROTECTING DEGRADABLE ORGANIC MATERIAL FROM FUNGAL OR INSECT ATTACK | SANKYO COMPANY LIMITED (JP) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129288-A1 | Antibacterial amide macrocycles | AADAC, AAAS, MRPL21 | NR1I2 859/4885ADRA2A 3738/4885ADORA3 3345/4885 |
| US-20060258571-A1 | Antibacterial ester macrocycles | TECR, MRPL21, CYP51A1 | NR1I2 170/4885ADRA2A 4310/4885ADORA3 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.